Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

NCT06074562 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06074562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06074562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
October 5, 2023
Completion date
June 11, 2025
Enrollment
404 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic peripheral neuropathy